石药创新制药拟H股上市，修订《公司章程（草案）》及部分治理制度

Core Viewpoint - The company is preparing for its H-share listing by revising its articles of association and governance structures to comply with regulatory requirements in both domestic and international markets [1][2]. Group 1: Articles of Association - The company held its 26th meeting of the sixth board of directors on September 30, 2025, to review multiple proposals related to the H-share issuance and listing [1]. - The revised articles of association cover various aspects including establishment basis, listing information, total shares, capital increase/decrease methods, share acquisition, transfer, shareholder rights and obligations, and the powers of the shareholders' and board meetings [1]. - Specific details such as the listing time and number of shares to be issued are included in the revised articles, which will take effect upon the H-share listing on the Hong Kong Stock Exchange [1]. Group 2: Governance Structure - The company is also revising and formulating several governance documents, including 17 key rules such as the "Rules of Procedure for Shareholders' Meetings" and "Rules of Procedure for Board Meetings" [2][3]. - The first four governance documents require approval from the shareholders' meeting, indicating a structured approach to governance reform [2]. - These adjustments are crucial for the company to align with the regulatory requirements of the capital markets and to enhance its governance structure [2].